Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

Go back to Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
(NASDAQ: STRO) Delayed: 10.79 -0.75 (6.5%)
Previous Close $11.54    52 Week High $ 
Open $11.62    52 Week Low $ 
Day High $11.80    P/E N/A 
Day Low $10.75    EPS $ 
Volume 439,854